Adinazolam

Jump to: navigation, search
Adinazolam
Adinazolam.png
Adinazolam00.png
Clinical data
Pregnancy
category
  •  ?
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • Schedule IV(US)
Pharmacokinetic data
Bioavailability?
MetabolismHepatic
Elimination half-life< 3 hours
ExcretionRenal
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC19H18ClN5
Molar mass351.8
3D model (JSmol)
  (verify)

WikiDoc Resources for Adinazolam

Articles

Most recent articles on Adinazolam

Most cited articles on Adinazolam

Review articles on Adinazolam

Articles on Adinazolam in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Adinazolam

Images of Adinazolam

Photos of Adinazolam

Podcasts & MP3s on Adinazolam

Videos on Adinazolam

Evidence Based Medicine

Cochrane Collaboration on Adinazolam

Bandolier on Adinazolam

TRIP on Adinazolam

Clinical Trials

Ongoing Trials on Adinazolam at Clinical Trials.gov

Trial results on Adinazolam

Clinical Trials on Adinazolam at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Adinazolam

NICE Guidance on Adinazolam

NHS PRODIGY Guidance

FDA on Adinazolam

CDC on Adinazolam

Books

Books on Adinazolam

News

Adinazolam in the news

Be alerted to news on Adinazolam

News trends on Adinazolam

Commentary

Blogs on Adinazolam

Definitions

Definitions of Adinazolam

Patient Resources / Community

Patient resources on Adinazolam

Discussion groups on Adinazolam

Patient Handouts on Adinazolam

Directions to Hospitals Treating Adinazolam

Risk calculators and risk factors for Adinazolam

Healthcare Provider Resources

Symptoms of Adinazolam

Causes & Risk Factors for Adinazolam

Diagnostic studies for Adinazolam

Treatment of Adinazolam

Continuing Medical Education (CME)

CME Programs on Adinazolam

International

Adinazolam en Espanol

Adinazolam en Francais

Business

Adinazolam in the Marketplace

Patents on Adinazolam

Experimental / Informatics

List of terms related to Adinazolam

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Adinazolam[1] (marketed under the brand name Deracyn) is a benzodiazepine derivative, and more specifically, a triazolobenzodiazepine (TBZD). It possesses anxiolytic, anticonvulsant, sedative, and antidepressant[2] properties. Adinazolam was developed by Dr. Jackson B. Hester, who was seeking to enhance the antidepressant properties of alprazolam, which he also developed.[3] Adinazolam was never FDA approved and never made available to the public market.

Indications

Adinazolam is indicated as a treatment for depression and anxiety.

Pharmacodynamics and pharmacokinetics

Adinazolam binds to peripheral-type benzodiazepine receptors that interact allosterically with GABA receptors as an agonist to produce inhibitory effects.

Metabolism

Adinazolam was reported to have active metabolites in the August 1984 issue of The Journal of Pharmacy and Pharmacology.[4] The main metabolite is N-desmethyladinazolam.[5] NDMAD has an approximately 25-fold high affinity for benzodiazepine receptors as compared to its precursor, accounting for the benzodiazepine-like effects after oral administration. (REF1) Multiple N-dealkylations lead to the removal dimethyl-aminoethyl side chain, leading to the difference in its potency. (REF5) The other two metabolites are alpha-hydroxyalprazolam and estazolam.[6] In the August 1986 issue of that same journal, Sethy, Francis and Day reported that proadifen inhibited the formation of N-desmethyladinazolam.[7]

See also

References

  1. FR Patent 2248050
  2. Lahti, Robert A.; Vimala H. Sethy; Craig Barsuhn; Jackson B. Hester (November 1983). "Pharmacological profile of the antidepressant adinazolam, a triazolobenzodiazepine". Neuropharmacology. 22 (11): 1277–82. doi:10.1016/0028-3908(83)90200-9. PMID 6320036.
  3. "Discovers Award 2004" (PDF). Special Publications. Pharmaceutical Research and Manufacturers of America. April 2004. p. 39. Archived from the original (PDF) on August 24, 2006. Retrieved August 18, 2006.
  4. Sethy, Vimala H.; R. J. Collins; E. G. Daniels (August 1984). "Determination of biological activity of adinazolam and its metabolites". Journal of Pharmacy and Pharmacology. 36 (8): 546–8. doi:10.1111/j.2042-7158.1984.tb04449.x. PMID 6148400.
  5. Peng, G. W. (August 1984). "Assay of adinazolam in plasma by liquid chromatography". Journal of Pharmaceutical Sciences. 73 (8): 1173–5. doi:10.1002/jps.2600730840. PMID 6491930.
  6. Fraser, A. D.; A. F. Isner; W. Bryan (November–December 1993). "Urinary screening for adinazolam and its major metabolites by the Emit d.a.u. and FPIA benzodiazepine assays with confirmation by HPLC". Journal of Analytical Toxicology. 17 (7): 427–31. doi:10.1093/jat/17.7.427. PMID 8309217.
  7. Sethy, Vimala H.; Jonathan W. Francis; J. S. Day (August 1986). "The effect of proadifen on the metabolism of adinazolam". Journal of Pharmacy and Pharmacology. 38 (8): 631–2. doi:10.1111/j.2042-7158.1986.tb03099.x. PMID 2876087.

Linked-in.jpg